A new bet on early heart failure detection and why women’s health is at the center.
Updated
January 8, 2026 6:28 PM
A doctor holding an artificial heart model. PHOTO: ADOBE STOCK
Heart disease does not always announce itself clearly, especially in women. Many of the symptoms are ordinary, including fatigue, shortness of breath and swelling. These signs are frequently dismissed or explained away. As a result, many women are diagnosed late, when treatment options are narrower and outcomes are worse. That diagnostic gap is the context behind a recent investment involving Ultromics and the American Heart Association’s Go Red for Women Venture Fund.
Ultromics is a health technology company that uses artificial intelligence to help doctors spot early signs of heart failure from routine heart scans. It has received a strategic investment from the American Heart Association’s Go Red for Women Venture Fund.
The focus of the investment is a long-standing blind spot in cardiac care. Heart failure with preserved ejection fraction, or HFpEF, affects millions of people worldwide, with women disproportionately impacted. It is one of the most common forms of heart failure, yet also one of the hardest to diagnose. Studies even show women are twice as likely as men to develop the condition and around 64% of cases go undiagnosed in routine clinical practice.
Ultromics works with a tool most patients already experience during heart care: the echocardiogram. There is no new scan and no added burden for patients. Its software analyzes standard heart ultrasound images and looks for subtle patterns that point to early heart failure. The goal is clarity. Give clinicians better signals earlier, before the disease advances.
“Heart failure with preserved ejection fraction is one of the most complex and overlooked diseases in cardiology. For too long, clinicians have been expected to diagnose it using tools that weren't built to detect it and as a result, many patients are identified too late,” said Ross Upton, PhD, CEO and Founder of Ultromics. “By augmenting physicians' decision making with EchoGo, we can help them recognize disease at an earlier stage and treat it more effectively.”
The stakes are high. Research suggests women are twice as likely as men to develop the condition and that a majority of cases are missed in routine clinical practice. That delay matters. New therapies can reduce hospitalizations and improve survival, but only if patients are diagnosed in time.
This is why early detection has become a priority for mission-driven investors. “Closing the diagnostic gap by recognizing disease before irreversible damage occurs is critical to improving health for women—and everyone,” said Tracy Warren, Senior Managing Director, Go Red for Women Venture Fund. “We are gratified to see technologies, such as this one, that are accepted by leading institutions as advances in the field of cardiovascular diagnostics. That's the kind of progress our fund was created to accelerate.”
Ultromics’ platform is already cleared by regulators for clinical use and is being deployed in hospitals across the US and UK. The company says its technology has analyzed hundreds of thousands of heart scans, helping clinicians reach clearer conclusions when traditional methods fall short.
Taken together, the investment reflects a broader shift in healthcare. Attention is shifting earlier—toward detection instead of reaction. Toward tools that fit into existing care rather than complicate it. In this case, the funding is not about introducing something new into the system. It is about seeing what has long been missed—and doing so in time.
Keep Reading
Connecting Chinese innovation with global markets through capital, collaboration and real-world deployment opportunities
Updated
March 30, 2026 2:29 PM
A Train Of Hong Kong's Mass Transit Railway (MTR) Metro System at Sunny Bay. PHOTO: ADOBE STOCK
As global tech ecosystems become more interconnected, the ability to move innovation across borders is becoming just as important as building it. A new partnership between MTR Lab, the investment arm of MTR Corporation and ZGC Science City Ltd, a government-backed technology ecosystem based in Beijing’s Haidian district, reflects this shift.
At its core, the collaboration is designed to connect high-potential Chinese startups with global capital, real-world deployment opportunities and international markets. It focuses on sectors like AI, robotics, smart mobility and sustainable urban development—areas where China already has strong technical depth but where scaling beyond domestic markets can be more complex.
This is where the partnership begins to matter. ZGC Science City sits at the center of one of China’s most concentrated innovation clusters, with thousands of AI companies and a growing base of specialised and high-growth firms. MTR Lab, on the other hand, brings access to international markets, industry networks and practical deployment environments tied to infrastructure, transport and urban systems. Together, they are attempting to bridge a familiar gap: turning local innovation into globally relevant products.
In practice, the model is straightforward. ZGC Science City will introduce MTR Lab to startups working in priority sectors, creating a pipeline for potential investment and collaboration. From there, MTR Lab can support these companies through funding, pilot projects and access to overseas markets. The idea is not just to invest, but to help startups test and apply their technologies in real-world settings, particularly in complex urban environments.
The timing is notable. China’s AI and deep tech ecosystem has expanded rapidly, with thousands of companies contributing to advancements in automation, smart infrastructure and sustainability. At the same time, global demand for these technologies is rising, especially as cities look for more efficient and scalable solutions. Yet, moving from innovation to adoption often requires cross-border coordination—something individual startups may struggle to navigate alone.
This partnership also builds on a broader pattern. Corporate venture arms like MTR Lab are increasingly positioning themselves not just as investors, but as connectors between markets. By combining capital with access to infrastructure and deployment scenarios, they offer startups a way to move faster from development to real-world use. For ZGC Science City, the collaboration adds an international layer to its ecosystem, helping local companies extend beyond domestic growth.
What emerges is a model that goes beyond a typical investment announcement. It reflects a growing recognition that innovation today is rarely confined to one geography. Technologies may be developed in one ecosystem, refined in another and scaled globally through partnerships like this.
As cross-border collaboration becomes more central to how startups grow, partnerships like the one between MTR Lab and ZGC Science City point to a more connected innovation landscape—one where access, not just invention, defines success.